Hearing Loss Clinical Trial Pipeline Insights Featuring 35+

New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) — Hearing Loss Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight

DelveInsight’s hearing loss pipeline report depicts a robust space with 35+ active players working to develop 45+ pipeline therapies for hearing loss treatment.

DelveInsight’s ‘Hearing Loss Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline hearing loss therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the hearing loss pipeline domain.

Key Takeaways from the Hearing Loss Pipeline Report

• DelveInsight’s hearing loss pipeline report depicts a robust space with 35+ active players working to develop 45+ pipeline therapies for hearing loss treatment. 
• Key hearing loss companies such as Sensorion, Pipeline Therapeutics, Frequency Therapeutics, Otonomy, Inc., Strekin AG, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Sound Pharmaceuticals Incorporated, Novartis, Gateway Biotechnology, Inc., Decibel Therapeutics, Akouos, Acousia Therapeutics GmbH, AGTC, BridgeBio Inc., Lineage Cell Therapeutics, Inc., Rinri Therapeutics Ltd., Autifony Therapeutics, AudioCure Pharma GmbH, Anida Pharma Inc., Mogrify, Astellas Pharma Inc., Altamira Therapeutics, Myrtelle, Hoba Therapeutics, Perha Pharmaceuticals,  and others are evaluating new hearing loss drugs to improve the treatment landscape.
• Promising hearing loss pipeline therapies such as PIPE 505, FX-322, SENS-401, OTO-413, STR001, HY01, SPI-1005, CGF166, Zonisamide, DB-OTO, AAV.103, AAV.104, DB-020, AK-OTOF, ACOU085, ACOU082, OTO-825, OTO-6XX, OTO-510, ,BBP-815, FX-345, Auditory Neuronal Cell Therapy, AC102,  AP-001,  AM-111, HB-097, and others are under different phases of hearing loss clinical trials.
• In September 2022, Sensorion announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products…